Generex Biotechnology Corporation is conducting human clinical trials of Antigen Express synthetic avian influenza vaccine which is being regarded as one of the first studies to be conducted on man. For conducting trials, the company has entered into an agreement with Lebanese-Canadian Hospital based in Lebanon. Pre clinical trials are already going on since 2004. Peptide-synthesis technology was used for developing this vaccine and it successful it would emerge out as a cost effective treatment. The vaccine comprises of specific fragments of H5 protein extracted from the H5N1 influenza virus which has been modified for enhancing their potency in stimulating CD4+ T helper cells. With bird flu virus spreading at a fast pace and causing a lot of destruction, it is necessary that effective vaccine should be developed for curbing the flu and this trial is a step towards achieving it.